**Webinar #1: FASD: Screening, Assessment, and Diagnosis**

Faculty: Douglas Waite, MD FAAP

*Date: Wednesday, May 15, 2019*

*Time: 12:00-1:00pm ET*

Participant registration: <https://aap.webex.com/aap/onstage/g.php?MTID=e14320fc4581832f1efecf73ac0c730ba>

Session pre-test - FASD Screening Assessment and Diagnosis: <https://aap.co1.qualtrics.com/jfe/form/SV_cGbOOOvhiQxjazr>

About the Webinar

This webinar will focus on defining the terms used to describe the conditions that fall under the umbrella of fetal alcohol spectrum disorders (FASDs), describing the signs that may indicate prenatal alcohol exposure and a possible condition along the continuum of FASDs. Participants will be oriented to the diagnostic assessment including the areas of the brain affected by prenatal alcohol exposure, approaches to delivering the diagnosis, and indications for referral. Faculty will reinforce the benefits of a diagnosis and demonstrate how to address issues around stigma in both assessing for prenatal alcohol exposure and delivering a FASDs diagnosis.

Learning Objectives

At the end of this webinar, participants will be able to:

1. Describe diagnostic criteria for conditions along the continuum of FASDs.
2. Understand the differential diagnoses of FASDs.
3. Explain the importance of screening all patients for a history of in utero alcohol exposure.

**Webinar #2: Neurobehavioral Disorder associated with Prenatal Alcohol Exposure (ND-PAE)**

Faculty: Douglas Waite, MD FAAP

*Date: Wednesday, May 22, 2019*

*Time: 12:00-1:00 pm ET*

Participant registration: <https://aap.webex.com/aap/onstage/g.php?MTID=e5969e3807e6a6f489cab2018e6578d70>

Session pre-test – ND-PAE: <https://aap.co1.qualtrics.com/jfe/form/SV_2i6QBTb7UBu97BH>

About the Webinar

This webinar will focus on the factors in a patient’s medical history and clinical presentation that may indicate the presence of Neurobehavioral Disorder Associated with Prenatal Alcohol Exposure (ND-PAE). Participants will learn about the three domains in which children with this disorder struggle with behavior and developmental tasks. The definition of ND-PAE from the 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and related issues regarding more than minimal exposure to alcohol will be shared. The ways that ND-PAE may present in clinic through the developmental stages and strategies for managing care will be covered.

Learning Objectives

At the end of this webinar, participants will be able to:

1. Describe diagnosis of ND-PAE
2. Explain the importance of obtaining prenatal alcohol exposure information on
*EVERY* patient
3. Describe ND-PAE across development

**Webinar #3 Treatment Across the Lifespan for Persons with a Fetal Alcohol Spectrum Disorders**

Faculty: Douglas Waite, MD FAAP

*Date: Wednesday, May 29, 2019*

*Time: 12:15-1:15pm ET*

Participant registration: <https://aap.webex.com/aap/onstage/g.php?MTID=ec8cb4d9c41d8c85ea64b9fcfee711890>

Session pre-test – Treatment Across the Lifespan for Individuals with a FASD: <http://aap.co1.qualtrics.com/jfe/form/SV_7a23bhf18grym0Z>

About the Webinar

This webinar will aim to provide primary care clinicians with the tools they need to treat children with FASDs across the lifespan. The session will focus on identifying and managing neurobehavioral and medical concerns at different developmental stages. Participants will learn about medical, therapeutic, and pharmaceutical considerations. Faculty will present evidence-based interventions that are applicable to community-based primary care pediatricians. Specifically, approaches to building parent knowledge and working with the school system on individualized education programs (IEPs) and 504 Plans will be discussed. Support services and resources for providers, families, and teachers/schools will also be covered.

Learning Objectives

At the end of this webinar, participants will be able to:

1. Describe developmental and functional concerns for individuals with FASDs and their families.
2. Discuss the care of individuals with FASDs from infancy to adolescence.
3. Discuss support services and resources for families and providers.

For more information about the sessions, please contact Josh Benke, AAP FASD Program Manager, at jbenke@aap.org.

**Faculty**

Douglas Waite, MD is Division Chief of Developmental and Behavioral Pediatrics at Bronxcare Health System. He was previously medical director of The Keith Haring Clinic at Children’s Village, a community foster care agency and residential treatment center. Dr. Waite holds an appointment of Assistant Clinical Professor of Pediatrics at Mount Sinai Hospital and is a member of the AAP Executive Council on Foster Care, Adoption, and Kinship Care. He has worked with AAP at the national and state levels on raising awareness of the neurodevelopmental effects of prenatal alcohol and substance exposure and is a participant in two panels formed by the AAP, Center for Disease Control and US Administration for Children and Families to develop protocols for screening children in child welfare and the general pediatric population for fetal alcohol and drug exposure. Dr. Waite is board-certified in developmental-behavioral pediatrics and is a member of the board of directors for the National Organization for Fetal Alcohol Syndrome, the Child Welfare League of America and the New York State American Academy of Pediatrics (NYS AAP), District II. Dr. Waite has special interests in fetal alcohol spectrum disorders, post-traumatic stress disorder and the effects of child abuse and neglect upon child development.